Diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs) with
mutated histone H3 K27M (H3-K27M),,,–are aggressive and universally fatal pediatric brain …

Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas
(DMGs) are universally lethal paediatric tumours of the central nervous system. We have …

Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive
subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide …

Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …

Glioblastoma is the most malignant primary brain tumor and is still in need of effective
medical treatment. We isolated patient-derived glioblastoma cells showing high GD2 …

The median overall survival for children with diffuse intrinsic pontine glioma (DIPG) is less
than one year. The majority of diffuse midline gliomas, including more than 70% of DIPGs …

Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

Diffuse intrinsic pontine glioma (DIPG) remains a fatal brainstem tumor demanding
innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) …

Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective
responses in adults with glioblastoma, but the feasibility and tolerability of this approach is …

Glioblastomas are aggressive primary brain tumors with an inherent resistance to T cell-
centric immunotherapy due to their low mutational burden and immunosuppressive tumor …